NAYA Biosciences (NAYA) nominates new Board members

NAYA Biosciences (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, today announced that its board of directors has nominated five new candidates with extensive experience in in the biotechnology industry to be approved at the company shareholder meeting scheduled for March 10th, 2025.

Laurent Audoly, PhD is the cofounder and CEO of PriveBio, a precision medicine company, and a professor and strategic advisor at the Institute for Experiential AI at Northeastern University. He has previously founded and scaled several biotechs across multiple therapeutic areas and serves as a board member of several companies. Dr. Audoly was the founding president and CEO of Kymera Therapeutics (NASDAQ: KYMR) and an advisor at Atlas Venture. Dr. Audoly previously held leadership positions in R&D at Pfizer, Merck and Pierre Fabre Group, where he was the global head of Research & Development and played a pivotal role in eight drug approvals. He holds a PhD in Pharmacology from the Vanderbilt University School of Medicine and completed his post-doctoral fellowship at UNC-Chapel Hill and Duke University.

Melissa Fensterstock, MPhil, MBA is an advisor with Material Impact Fund since 2023, where she helps early-stage companies translate innovations from academic settings to commercial scale. Ms. Fensterstock previously served as CEO and board member of Lansdowne Labs, a spin-out from MIT and Harvard founded by Professors Robert Langer and Jeffrey Karp. She has also held executive-in-residence positions at Columbia University, Johns Hopkins University, Yale University, and Climate Haven. Ms. Fensterstock holds a Master in Business Administration from Harvard Business School, a Master of Philosophy in Bioscience Enterprise from the University of Cambridge, and a B.A. in Neuroscience from Johns Hopkins University.

Prakash Raman, PhD is the CEO of InduPro, Inc., a venture-backed protein therapeutics company. He is also a director at Black Diamond Therapeutics, Inc. (NASDAQ: BDTX). He previously served as Chief Business Development Officer at Flagship Pioneering and spent nearly fourteen years at Novartis, most recently as VP, Global Health of Novartis Institutes for Biomedical Research (NIBR), Business Development and Licensing (BD&L), where he was instrumental in forging key collaborations in immuno-oncology, executing numerous out-licensing opportunities, and guiding the acquisitions of Advanced Accelerator Applications, Endocyte, IFM Tre, and Selexys. He received his Ph.D. in Organic and Medicinal Chemistry from the University of Wisconsin-Madison and spent two years as a post-doctoral fellow at The Scripps Research Institute.

Daniel Teper, PharmD, MBA is the Founder & President of NAYA Biosciences. He is also the Executive Chairman of Imaginostics and a member of the supervisory board of Crossject (Euronext: ALCJ.PA). Previously, Dr. Teper served as the Chairman & CEO of Cytovia Therapeutics, CEO of Immune Pharmaceuticals (where he led the company to its NASDAQ-listing), Managing Partner, Head of North America at Bionest Partners (now Accenture), Partner at ISO Healthcare (now Deloitte), SVP of Sales & Business Development at Softwatch, a pioneer digital health company, Global President of Havas Health, a leading communications group, and has held senior management positions at Novartis, GlaxoSmithKline, and Sanofi. He holds a Doctor of Pharmacy degree from Paris XI University and an MBA from INSEAD, where he was the J. Salmon scholar.

Alexandra Urman, MPH is an analyst and portfolio manager at the intersection of biotechnology and healthcare innovation. Ms. Urman currently serves as the CEO of Aomics and Senior Vice President of the Florida-Israel Business Accelerator’s Venture Fund. She previously served at ARK Investments, where she focused on their Genomic Revolution strategy. Ms. Urman serves as a board member of Cure Rare Disease and an advisor for the Stanford School of Medicine’s SPARK program. Ms. Urman started her career in clinical cancer research at Memorial Sloan Kettering Cancer Center and Montefiore Medical Center and as a Senior Research Program Manager at IBM Watson Health, where she championed the integration of AI in healthcare. Ms. Urman holds a B.A. from McGill University and a Master’s in Epidemiology and Community Health from New York Medical College.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Paramount Skydance clears global regulators for WBD deal, faces state AG suit
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c